# Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study

> **NCT04012918** · PHASE2 · UNKNOWN · sponsor: **Ain Shams University** · enrollment: 124 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Capecitabine plus aromatase inhibitor
- **DRUG:** A.I.

## Key facts

- **NCT ID:** NCT04012918
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-30
- **Primary completion:** 2020-08
- **Final completion:** 2021-02
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2019-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04012918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04012918, "Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04012918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*